Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Global Strategic Partners, LLC
 2. Date of Event Requiring Statement (Month/Day/Year)
11/14/2008		 3. Issuer Name and Ticker or Trading Symbol
MICROFLUIDICS INTERNATIONAL CORP [MFLU]
(Last)
(First)
(Middle)
C/O CORPORATION SERVICE COMPANY, 2711 CENTERVILLE ROAD, SUITE 400		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WILMINGTON, DE 19808		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
9% Convertible Debenture 01/01/2009 11/14/2015 Common Stock 4,000,000 $ 1.25 D (1)  
Warrant 11/14/2009   (2) Common Stock (3) $ (3) D (1)  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Global Strategic Partners, LLC
C/O CORPORATION SERVICE COMPANY
2711 CENTERVILLE ROAD, SUITE 400
WILMINGTON, DE 19808		     X    
Abraxis BioScience, LLC
11755 WILSHIRE BLVD.
SUITE 2000
LOS ANGELES, CA 90025		     X    
Abraxis BioScience, Inc.
11755 WILSHIRE BLVD.
SUITE 2000
LOS ANGELES, CA 90025		     X    

Signatures

/s/ Bruce Wendel 11/24/2008
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Convertible Debenture and the Warrant are owned directly by Global Strategic Partners, LLC, which is a wholly-owned subsidiary of Abraxis BioScience, LLC, which is a wholly-owned subsidiary of Abraxis BioScience, Inc. Abraxis BioScience, LLC and Abraxis BioScience, Inc. are indirect beneficial owners of the reported securities.
(2) The Warrant is exercisable until the earlier of (i) seven (7) years, (ii) the third anniversary if the Convertible Debenture has been converted into shares of the issuer's common stock or (iii) the date that the Global Strategic Partners holds 50% of the issuer's outstanding common stock.
(3) The Warrant is exercisable in two (2) tranches. The first tranche is exercisable in whole or in part at $2.00 per share. The aggregate number of shares of issuer's common stock that may be purchased in tranche one is forty percent (40%) of the issuer's common stock then outstanding on a fully diluted basis, minus that number of shares of issuer's common stock that were issuable upon exercise of the conversion of the Debenture. The Warrant's second tranche is exercisable in whole or in part at $3.00 per share. The aggregate number of shares of the issuer's common stock that may be purchased in tranche two is equal to fifty percent (50%) of the issuer's common stock then outstanding on a fully diluted basis, minus the sum of that number of shares of Issuer's common stock that were issuable upon exercise of the conversion of the Debenture and in tranche one.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.